Study: Food imported from countries with low GDP poses higher risks

Study: Food imported from countries with low GDP poses higher risks

Analysis says 'size of a country's economy appears to be a more important determinant of food safety than its wealth.'

Food imported into the United States from countries with a low gross domestic product poses higher risks than food from richer countries, according to a new study analyzing 10 years’ worth of U.S. Food and Drug Administration data on food import violations.

The novel analysis of FDA’s 2002-2007 data on food import violations suggests that “the size of a country’s economy appears to be a more important determinant of food safety than its wealth,” or GDP per capita, according to the study, “Import Security: Assessing the Risks of Imported Food.”

A study found that imported food from countries with a low domestic product pose higher risks.

The research was conducted by Jonathan Welburn and Vicki Bier, of the University of Wisconsin−Madison Department of Industrial and Systems Engineering, and Steven Hoerning, of Stanford University’s Graduate School of Business. It was published in the online version of Risk Analysis, a publication of the Society for Risk Analysis.

“We present a novel use of existing data to provide partial answers on food import risks that are not easy to obtain by other means,” Welburn said. “Our results suggest that the risk level of imported food is higher for foods from low-GDP countries. High-GDP countries, on the other hand, may be better able to reduce risks through standards and regulations. Consequently, importers may wish to pay more for products from high-GDP countries, or work closely with suppliers from low-GDP countries to ensure good safety practices.”

To quantify imported food risks, the researchers used FDA Inspection Refusal Report data. FDA generates an IRR when its inspectors refuse to admit a shipment into the United States. Imports can be refused for botulism, filth, rotting foods, or other blatant food-safety concerns, as well as for “less dramatic violations,” such as the lack of required documentation. FDA only needs to prove the appearance of a violation, not an actual violation, so a refusal is “not an absolute measure of risk, and is interpreted as a proxy for risk,” according to the paper.

The complete study is available at: http://onlinelibrary.wiley.com/wol1/doi/10.1111/risa.12560/abstract

Source: Risk Analysis: An International Journal

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish